Overview

MOTIVATED TO MAKE BETTER DRUGS -POWERED WITH TUMOR DATA -DELIVERED BY MACHINE LEARNING

Today is one of those goose‑bump moments at Gordion Bioscience !We’ve officially licensed out our MTAP‑deleted‑tumour programme to the brilliant minds at Kohde Pharma .This licensing deal proves and underscores our firm believe that patient data+AI outshine cell‑line models. Why? Because our platform can uncover cancer vulnerabilities that just aren’t visible in cell lines. This opens the doors to uncovering entirely new targets and, ultimately, better treatment outcomes.

Why this milestone matters: MTAP deletions appear in ~15% of all cancers, yet patients still lack targeted options. Kohde Pharma has full access to Gordion’s AI‑powered platform. Gordion mined real patient data and uncovered new synthetic‑lethal targets.

Huge congratulations to Thomas Wirth , Pawel Zawadzki , and the entire teams at Kohde Pharma and Gordion Bioscience for making this happ...